Adicet BioFRA:1IJ 31 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates FRA:1IJ with a GF Score™ of 31/100. The stock has 2 warning signs investors should review. Among 699 Biotechnology companies, Adicet Bio ranks worse than 143061.37% on this metric.
The historical rank and industry rank for Adicet Bio's Days Payable or its related term are showing as below:
FRA:1IJ's Days Payable is not ranked *
in the Biotechnology industry.
Industry Median: 112.84 * Ranked among companies with meaningful Days Payable only.
Adicet Bio's Days Payable
stayed the same
from Mar. 2025 (0.00) to Mar. 2026 (0.00).
stayed the same
Adicet Bio Days Payable Related Terms
Adicet Bio Days Payable Historical Data
* Premium members only.
The historical data trend for Adicet Bio's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:1IJ vs EDSA, GOSS, HRTX: Days Payable Comparison
For the Biotechnology subindustry, Adicet Bio's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Adicet Bio Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Adicet Bio's Days Payable distribution charts can be found below:
* The bar in red indicates where Adicet Bio's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Adicet Bio's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Adicet Bio (FRA:1IJ) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Adicet Bio and its competitors. According to the industry distribution chart, Adicet Bio ranks #999999 out of 699 companies in the Biotechnology industry.
Is Adicet Bio's Days Payable too high?
Adicet Bio's current Days Payable is 0.00. Based on the distribution chart, Adicet Bio ranks #999999 out of 699 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Adicet Bio has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Adicet Bio's Days Payable compare to EDSA and GOSS?
According to the Biotechnology industry distribution chart, Adicet Bio ranks #999999 out of 699 companies for Days Payable. This places Adicet Bio in the lower half of its industry. The industry median Days Payable is 112.84. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 699 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Adicet Bio and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Adicet Bio's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Adicet Bio stock overvalued right now?
Adicet Bio (FRA:1IJ) has a current Days Payable of 0.00. The current Days Payable is 0.00. Adicet Bio's overall GF Score™ is 31/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Adicet Bio (FRA:1IJ), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer. It is advancing a pipeline of off-the-shelf gamma delta T cells, engineered with chimeric antigen receptors (CARs), to facilitate durable activity in patients. The company's main product candidate, prulacabtagene leucel (prula-cel), is an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, and is being developed for the potential treatment of autoimmune diseases. Additionally, it is pursuing ADI-212, a next-generation gene-edited and armored clinical candidate designed to target prostate-specific membrane antigen (PSMA).
31GF Score
Get the complete analysis for FRA:1IJ
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:1IJ has been successfully added to your 
